Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Not prohibited · ingredient only
WADA 2026: an explicit S5 exception, retained in the future 2027 List. This does not clear every ingredient in a combination product. [1] [2]
2026 and 2027 List, S5, printed p.12; introductory definitions p.3 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical and pharmacological context
The US Slynd label describes a progestin-only oral contraceptive. Its main contraceptive action is suppression of ovulation. Drospirenone has antimineralocorticoid activity, but WADA expressly excepts it from S5. [3]
- The cited country-specific product information does not establish worldwide authorization or current supply.
Health concerns
The product can raise blood potassium, especially in patients with relevant kidney, liver or adrenal disease or with interacting medicines. This label should not be used as the safety label for estrogen-containing combinations. [3]
- Selected warnings, not a complete contraindication or interaction list. Patient-label evidence does not establish athlete safety.
What remains uncertain
- Do not infer a prohibited-diuretic TUE requirement solely from pharmacological similarity. The S5 threshold-combination note explicitly names only the eye and dental exclusions; uncertain combinations require authoritative interpretation.
- Educational synthesis only; not individualized medical advice, a TUE decision or a sanction prediction.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Introduction p.3 · S5 p.12
- WADA 2027 Prohibited List, 4 November revision ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected · FUTURE 2027 SOURCE
Introduction p.3 · S5 p.12
- DailyMed Slynd drospirenone ↗Accessed 2026-11-10 · relevant full-text sections independently opened and inspected
Indications; clinical pharmacology or SmPC sections 4.1 and 5.1 · Warnings, precautions and adverse reactions
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.